[May 15, 2012] Shares of Protalix BioTherapeutics Rank the Highest in Terms of Forward P/E Ratio in the Biotechnology Industry (PLX, CPHD, REGN, ALXN, LGND) Tweet May 15, 2012 (SmarTrend(R) News Watch via COMTEX) -- Below are the three companies in the Biotechnology industry with the highest forward price to earnings (P/E) ratios. Forward P/E uses estimated earnings to compare relative value among companies in the same industry. Generally, the lower the forward P/E, the more undervalued a company is believed to be.Protalix BioTherapeutics ranks highest with a a forward P/E ratio of 92.86. Following is Cepheid with a a forward P/E ratio of 49.32. Regeneron Pharmaceuticals ranks third highest with a a forward P/E ratio of 40.73. Alexion Pharmaceuticals follows with a a forward P/E ratio of 33.84, and Ligand Pharmaceuticals rounds out the top five with a a forward P/E ratio of 32.00. SmarTrend recommended that its subscribers protect gains by selling shares of Ligand Pharmaceuticals on April 4th, 2012 by issuing a Downtrend alert when the shares were trading at $15.37. Since that call, shares of Ligand Pharmaceuticals have fallen 19.6%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time. Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup [ Back To TMCnet.com's Homepage ]